Evid Based Nurs 6:20 doi:10.1136/ebn.6.1.20
  • Treatment

Oestrogen plus progestin increased coronary heart disease and breast cancer in postmenopausal women

 QUESTION: In postmenopausal women, what are the risks and benefits of oestrogen plus progestin use, particularly with respect to coronary heart disease (CHD) events?


Randomised (allocation concealed), blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee), placebo controlled trial with a mean 5.2 years of follow up.


40 US clinical centres.


16 608 postmenopausal women who were 50–79 years of age (mean age 63.3 y) with an intact uterus at baseline. Exclusion criteria included medical conditions associated with probable survival of <3 years, previous breast cancer or other cancer in the past 10 years (except non-melanoma skin cancer), low hematocrit or platelet counts, and adherence and retention concerns (eg, alcoholism and dementia). Follow up was 96.5%.


Women were allocated to 1 daily tablet of conjugated equine oestrogen, 0.625 mg, and medroxyprogesterone acetate, 2.5 …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article